DBV Technologies (DBVT) CMO sells 534 shares to cover taxes

Rhea-AI Filing Summary

DBV Technologies S.A. Chief Medical Officer Mohideen Pharis reported a small insider sale of company stock. On January 29, 2026, Pharis sold 534 ordinary shares of DBV Technologies at a price of $4.86 per share, primarily to satisfy withholding tax obligations linked to vesting restricted stock units. After this transaction, Pharis beneficially owned 144,995 ordinary shares, held directly. The filing also notes that DBV Technologies’ ordinary shares may be represented by American Depositary Shares, with each ADS currently representing five ordinary shares.

Insider Trade Summary

Net Seller: 534 shares ($2,595)

Net Sell 1 txn

Insider Mohideen Pharis

Role Chief Medical Officer

Sold 534 shs ($3K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	534	$4.86	$3K

Holdings After Transaction: Ordinary Shares — 144,995 shares (Direct)

Footnotes (1)

1. The ordinary shares may be represented by American Depositary Shares, each of which currently represents five ordinary shares. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.1974 to EURO 1.00 as of January 29, 2026.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 02/02/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mohideen Pharis

(Last) (First) (Middle)

C/O DBV TECHNOLOGIES S.A.

107, AVENUE DE LA REPUBLIQUE

(Street)

CHATILLON I0 92320

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
DBV Technologies S.A. [ DBVT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/29/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	01/29/2026		S(2)		534(3)	D	$4.86	144,995	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The ordinary shares may be represented by American Depositary Shares, each of which currently represents five ordinary shares.

2. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units.

3. This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.1974 to EURO 1.00 as of January 29, 2026.

	/s/ Virginie Boucinha, Attorney-in-Fact	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did DBV Technologies (DBVT) report for its CMO?

DBV Technologies’ Chief Medical Officer Mohideen Pharis reported selling 534 ordinary shares. The sale occurred on January 29, 2026, at $4.86 per share, and was disclosed as a routine insider transaction on a Form 4 filing.

Why did DBV Technologies (DBVT) CMO sell 534 ordinary shares?

The 534 ordinary shares were sold to satisfy withholding tax obligations triggered by the vesting of restricted stock units. This indicates the sale was related to tax requirements rather than a discretionary liquidation of a large personal holding.

How many DBV Technologies (DBVT) shares does the CMO own after the sale?

After the January 29, 2026 transaction, Chief Medical Officer Mohideen Pharis beneficially owned 144,995 ordinary shares of DBV Technologies. These shares are reported as held directly, following the small tax-related sale of 534 shares.

At what price were the DBV Technologies (DBVT) shares sold by the CMO?

The 534 ordinary shares sold by DBV Technologies’ Chief Medical Officer were transacted at a price of $4.86 per share. This per-share price is stated directly in the Form 4 insider transaction details for January 29, 2026.

How are DBV Technologies (DBVT) ordinary shares related to American Depositary Shares?

DBV Technologies states that its ordinary shares may be represented by American Depositary Shares. Each American Depositary Share currently represents five ordinary shares, providing a way for investors to hold the company’s equity through ADS instruments.

What role does Mohideen Pharis hold at DBV Technologies (DBVT)?

Mohideen Pharis serves as Chief Medical Officer at DBV Technologies. The Form 4 filing identifies Pharis as an officer of the company, not a director or 10% owner, and reports direct beneficial ownership of the ordinary shares involved.